AD positivity was defined as being Aβ and tau positive according to the criteria of the National Institute of Aging-Alzheimer’s Association13 and the International Working Group4 and LB positivity as being α-syn SAA-positive; AD and LB positivity refer to the biomarker status, not the clinical diagnoses, which were determined differently and not included in any statistical analyses (Methods)14. This evidence concerns the gene MAPT and Alzheimer disease.